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Abstract
Recent reports have implicated the NLRP3-associated inflammasome in the adjuvanticity of alum.
Here, we summarize the major findings and ask what this may mean for improving human vaccination.
Introduction and context
Since the first report by Glenny et al. [1] that diphtheria
toxoid precipitated with aluminum salt generated
significantly better immune responses, aluminum-con-
taining adjuvants (alum, aluminum hydroxide) have
become the most widely used in human vaccines.
Although safe and efficacious, the mechanism of action
has remained obscure. Models have shifted from the
capacity of adjuvants to establish depots promoting the
slow and sustained release of antigen from the injection
site, to current hypotheses acknowledging the key role of
the innate immune system in providing cytokines and
co-stimulatory pathways important for overcoming
activation thresholds for adaptive immunity. In this
model, adjuvants mimic signals from microbes whose
recognition has been hardwired into innate immune
recognition structures, as best exemplified by the Toll-
like receptors. Alum provokes an antibody response,
characterized by a predominance of immunoglobulin G
1 (IgG1) and immunoglobulin E (IgE), that is associated
with Th2-mediated immunity [2], however, and host
recognition elements associated with such responses
remain incompletely defined.
Major recent advances
Recently, several papers have implicated components of
the inflammasome in the adjuvant activity of alum. The
inflammasome is a cytosolic intermolecular platform
assembled in response to a variety of cellular perturba-
tions and leads to the activation of caspase-1 from its
inactive procaspase form. In turn, active caspase-1
processes the proforms of several interleukin (IL)-1-
family cytokines, including IL-1b, IL-18 and IL-33 [3],
and mediates cell death. Each of the reports investigating
alum implicate the inflammasome containing NLRP3
(NALP3, cryopyrin, CIAS1), a member of the nucleotide-
binding domain-and leucine-rich repeat-containing
family of proteins, and an adaptor protein, ASC
[apoptosis-associated speck-like protein containing a
caspase recruitment domain (CARD)], raising questions
of how alum is sensed by the host. Although different
approaches and experimental detail preclude complete
assessment, several [4–6], but not all [7], of the groups
show that the alum-induced IgE and/or IgG1 response
requires NLRP3, although all seem to agree that alum
induces IL-1 family members through the NLRP3-
mediated activation of caspase-1.
The NLRP3-associated inflammasome can be activated
by structurally diverse molecules, including ATP [8–10],
gout-associated crystals [monosodium urate (MSU) or
calcium pyrophosphate dehydrate] [11], pore-forming
toxins (nigericin, maitotoxin, aerolysin, streptolysin O)
[8,9,12], bacterial RNA, antiviral imidazoquinoline
compounds R837 and R848 [13], skin sensitizers
[10,14], fibrillar amyloid b [15] and particulate mole-
cules, including asbestos, silica and, as recently shown,
alum [4–7,16–18]. Confirmation of a few of these effects
is lacking, but it still remains an enigma how NLRP3 can
recognize such heterogeneous structures. Pore-forming
toxins or ATP activation of P2X7 receptors trigger
potassium ion (K
+) efflux from the cell [19]. Conversely,
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+ depletion inhibits activation of the NLRP3-
inflammasome by these agents, as well as by crystal-like
particulates, including alum [4,6,12,16,17,20,21].
Recombinant ASC forms oligomeric complexes at sub-
physiological K
+ concentrations, suggesting an impor-
tant role for K
+ efflux in promoting inflammasome
assembly [21]. The finding that ATP and uric acid crystals
released from damaged or dying cells activated the
NLRP3 inflammasome raised the possibility that the
inflammasome responded to endogenous signals of
tissue injury [so-called danger-associated molecular
patterns (DAMPs)] as originally proposed by Matzinger
[22], rather than to specific microbial ligands [pathogen-
associated molecular patterns (PAMPs)] as recognized by
the Toll-like receptors. Importantly, however, only the
crystalline forms of uric acid (MSU) and alum activate
dendritic cells in vitro; the soluble forms are inactive [23].
Uric acid does not appear to be an intermediary during
activation of the NLRP3 inflammasome pathway by
silica, asbestos or alum, however, since uricase does not
block inflammasome activation [4–6,16,18]. Thus, the
commonality for inflammasome activation by these
substances is their physical form as crystals, consistent
with the longstanding observation that particulates work
as adjuvants.
Recently, Hornung et al. [18] showed that silica, MSU
crystals and alum taken up by actin-dependent phago-
cytosis ultimately cause destabilization of lysosomes,
with swelling, increasing pH and eventual rupture of
lysosomal contents into the cytosol. Further, the induc-
tion of lysosomal rupture activated the NLRP3 inflam-
masome, even in the absence of other stimuli. Cathepsin
B released from the lysosome into the cytosol was critical
for activation of caspase-1 under these conditions
(Figure 1). Cathepsin B has been previously associated
with necrosis-like cell death. The pore-forming toxin,
nigericin, induces rapid lysosmal leakage and re-location
of cathepsin B into the cytosol [24], leading to caspase-1-
independent, but cathepsin B-dependent, death, called
pyronecrosis [25]; blocking cathepsin B activity impaired
lysosomal leakage [26]. Moreover, NLRP3 mutations
associated with human inflammatory syndromes induce
a similar cathepsin B-dependent death pathway [26,27].
It is still not clear whether cathepsin B acts upstream or
downstream of inflammasome activation, whether
cathepsin B is directly sensed or plays a role in generating
Figure 1. Alum-induced NLRP3 inflammasome activation
Phagocytosed alum-containing lysosomes rupture and release their components to the cytosol by an unknown mechanism. The released contents and
molecules generated during this process contribute to NLRP3/ASC/caspase-1 inflammasome activation, which in turn processes the proforms of IL-1 family
members to active forms. Either IL-1 family member cytokines or the products from NLRP3 inflammasome activation may elicit various immunostimulatory
effects in vivo. When and how potassium efflux and reactive oxygen species (ROS) play a role awaits further investigation. DC, dendritic cell; MSU,
monosodium urate.
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and induction of pyronecrosis is a necessary step for
activation of NLRP3. In addition, reactive oxygen species
play a role in ATP or crystal-induced inflammasome
activation [6,16,17], but the details of the inter-relation-
ship between K
+ efflux, reactive oxygen species, lysoso-
mal disruption, and, finally, their physiological
significance in generating enhanced antibody responses
remain unknown. Finally, the mechanism by which
particulates result in lysosomal destabilization remains
unclear, although the possibility exists that physical
rupture of the membrane due to the irregularities of the
crystalline substances is itself the common underlying
pathway.
Future directions
An important question is whether the IL-1 family
cytokines generated by the alum-activated NLRP3
inflammasome are critical for isotype switching to IgG1
and IgE. Alum induces neutrophil-rich granulomas at the
injection site [28]. When injected into the peritoneum or
trachea, alum or silica elicited neutrophil and monocyte
recruitment by an IL-1/IL-1 receptor/MyD88 pathway
[18,29]. Monocytes recruited by alum process co-injected
antigens, mature, migrate to the draining lymph nodes
and expand antigen-specific T cells through a process in
part dependent on NLRP3 [6,29]. Whether these mono-
cytes are required for enhanced antibody responses
remains unanswered. Although IL-1 has been shown to
increase antigen-specific T cells [30], IL-1R1-deficient
mice generated normal antigen-specific antibody
responses following intraperitoneal immunization in
models using trinitrophenol-keyhole limpet hemocya-
nin and asthma [31,32]. IL-18 can increase IgE produc-
tion and Th2 cytokines [33,34], but IgG1 and IgE
production was not affected by IL-18 deficiency [35].
IL-33 stimulates production of IL-4, IL-5 and IL-13 [36].
However, deletion of the IL-33 receptor, T1/ST2, did not
impair the alum-induced asthma response [37]. The lack
of defects in the individual knockout mice may be due to
redundant functions among IL-1 family members. All
three of these IL-1 family members share MyD88 for
signaling [38], however, and IgG1 production was
normal in MyD88-deficient mice immunized with
ovalbumin and alum [4,39] and no defect in antibody
production was seen using mice genetically deficient in
both MyD88 and TRIF (Myd88
-/-; Trif
Lps2/LpsS2 mice)
challenged with trinitrophenol-hemocyanin [40]. There-
fore, until the possibility of a MyD88-independent
signaling pathway is shown, the involvement of IL-1
family members in the alum response remains
inconclusive.
Most of the in vitro experiments in these various reports
used macrophages and/or human monocytic cell lines.
Since dendritic cells (DCs) play a critical role in T cell
activation and differentiation, an important question
remains whether alum programs DCs to enhance a Th2-
mediated immune response through activation of the
NLRP3 inflammasome. Alum induced in vitro DC
differentiation, as measured by upregulation of co-
stimulatory molecules, in one [41], but not other studies
[23,42]. Alum generated uric acid in vivo [29], which
could lead to crystalline MSU particles able to induce DC
maturation. Indeed, the alum-induced recruitment of
monocytes to the draining lymph nodes was abrogated
by uricase treatment [29]. DC activation may be
regulated at the level of caspase-1 or ASC, and not by
IL-1 family members. Caspase-1 has been shown to
cleave many substrates that can regulate cell survival and
tissue repair [43]. Toxin-mediated K
+ depletion induces
sterol regulatory element binding protein (SREBP)
activation via caspase-1, potentially leading to activation
of membrane repair pathways [12]. It is also possible
that alum facilitates Th2-associated immune responses
independent of DCs. Alum recruits IL-4-expressing Gr1
+
cells to the spleen where these cells could prime B cells
[44–46] and suppress Th1-associated antibody responses
[46]. Further study of the alum (or crystal)-induced
inflammasome may provide insights into the integration
of signals by the inflammasome and the molecular
pathways that trigger Th2-associated immune responses,
even beyond the antibody-enhancing effects of adju-
vants, and greatly improve our capacityto design rational
vaccine adjuvants for use in humans as well.
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